Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies

KRAS G12C inhibition and innate immune targeting

(2021) Tetsuo Tani et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the ETOP Lungscape Project

(2021) Stephen P. Finn et al.   Journal of Thoracic Oncology

Targeting KRAS in Cancer: Promising Therapeutic Strategies

(2021) Lisa Maria Mustachio et al.   Cancers

KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma

(2021) Nikolaj Frost et al.   Translational Lung Cancer Research

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

(2021) G.J. Riely et al.   Journal of Thoracic Oncology

KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from the in vitro experiments

(2021) Takamasa Koga et al.   Journal of Thoracic Oncology

Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy

(2021) A.L. Noordhof et al.   LUNG CANCER

Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment

(2021) D. Lucas Kerr et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Driver mutations to predict for poorer outcomes in non-small cell lung cancer patients treated with concurrent chemoradiation and consolidation durvalumab.

(2021) Yufei Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

(2021) Ferdinandos Skoulidis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor

(2021) Xiaolun Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial

(2020) S.I. Ou et al.   Journal of Thoracic Oncology

STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype

(2020) Carminia M. Della Corte et al.   Journal of Thoracic Oncology

Targeting the MAPK Pathway in KRAS-Driven Tumors

(2020) Matthias Drosten et al.   CANCER CELL

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

(2020) Ramesh K. Ramanathan et al.   Targeted Oncology

Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment

(2020) Lucia Nogova et al.   Cancer Medicine

1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations

(2020) H. West et al.   ANNALS OF ONCOLOGY

Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer

(2020) Matthew J. LaMarche et al.   JOURNAL OF MEDICINAL CHEMISTRY

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

(2020) David S. Hong et al.   NEW ENGLAND JOURNAL OF MEDICINE

BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition

(2020) Marco H Hofmann et al.   Cancer Discovery

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

(2020) Jonathan W. Goldman et al.   Frontiers in Oncology

Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo

(2020) Kotaro Sakamoto et al.   Scientific Reports

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

(2019) Badi El Osta et al.   Journal of Thoracic Oncology

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

(2019) Ferdinandos Skoulidis et al.   JOURNAL OF CLINICAL ONCOLOGY

Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front

(2019) Maria Saigi et al.   ONCOGENE

ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway

(2018) Andrew M. Kidger et al.   PHARMACOLOGY & THERAPEUTICS

Afatinib restrains K-RAS–driven lung tumorigenesis

(2018) Herwig P. Moll et al.   Science Translational Medicine

The ERBB network facilitates KRAS-driven lung tumorigenesis

(2018) Björn Kruspig et al.   Science Translational Medicine

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

(2018) Ferdinandos Skoulidis et al.   Cancer Discovery

LBA15Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas

(2018) K J Harrington et al.   ANNALS OF ONCOLOGY

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

(2018) Francesco Passiglia et al.   BRITISH JOURNAL OF CANCER

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer

(2018) Shunsuke Kitajima et al.   Cancer Discovery

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer

(2016) C. A. Carter et al.   ANNALS OF ONCOLOGY

Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer

(2016) Sophie Broutin et al.   BRITISH JOURNAL OF CANCER

IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer

(2016) M. S. Caetano et al.   CANCER RESEARCH

IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis

(2016) G. D. Brooks et al.   CANCER RESEARCH

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

(2016) S. Koyama et al.   CANCER RESEARCH

A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling

(2016) Sai Krishna Athuluri-Divakar et al.   CELL

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

(2016) M. P. Patricelli et al.   Cancer Discovery

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†

(2015) G. R. Blumenschein et al.   ANNALS OF ONCOLOGY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

(2015) F. Skoulidis et al.   Cancer Discovery

Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

(2014) A. W. Tolcher et al.   CLINICAL CANCER RESEARCH

KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma

(2014) Ernest Nadal et al.   Journal of Thoracic Oncology

Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers

(2012) Ramaswamy Govindan et al.   CELL

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

(2012) Pasi A Jänne et al.   LANCET ONCOLOGY

Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis

(2012) Hao-Hsuan Jeng et al.   Nature Communications

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

(2008) G. J. Riely et al.   CLINICAL CANCER RESEARCH